TD Private Client Wealth LLC Has $363,000 Holdings in iShares Biotechnology ETF (NASDAQ:IBB)

TD Private Client Wealth LLC raised its stake in iShares Biotechnology ETF (NASDAQ:IBB) by 3.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,746 shares of the financial services provider’s stock after purchasing an additional 81 shares during the period. TD Private Client Wealth LLC’s holdings in iShares Biotechnology ETF were worth $363,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in IBB. National Bank of Canada FI increased its position in shares of iShares Biotechnology ETF by 5.9% during the third quarter. National Bank of Canada FI now owns 4,124 shares of the financial services provider’s stock valued at $600,000 after purchasing an additional 229 shares during the period. IFP Advisors Inc increased its holdings in iShares Biotechnology ETF by 237.1% in the 4th quarter. IFP Advisors Inc now owns 16,018 shares of the financial services provider’s stock valued at $2,118,000 after buying an additional 11,266 shares during the period. Healthcare of Ontario Pension Plan Trust Fund raised its stake in shares of iShares Biotechnology ETF by 32.9% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 663,000 shares of the financial services provider’s stock valued at $96,533,000 after buying an additional 164,000 shares in the last quarter. Main Management ETF Advisors LLC lifted its holdings in shares of iShares Biotechnology ETF by 2.5% during the 3rd quarter. Main Management ETF Advisors LLC now owns 593,370 shares of the financial services provider’s stock worth $86,395,000 after acquiring an additional 14,535 shares during the period. Finally, Cullen Frost Bankers Inc. boosted its position in shares of iShares Biotechnology ETF by 1.5% during the 4th quarter. Cullen Frost Bankers Inc. now owns 5,654 shares of the financial services provider’s stock valued at $748,000 after acquiring an additional 82 shares in the last quarter. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Up 1.3 %

NASDAQ IBB opened at $135.31 on Tuesday. iShares Biotechnology ETF has a twelve month low of $123.60 and a twelve month high of $150.57. The stock has a market cap of $6.39 billion, a P/E ratio of 27.83 and a beta of 0.84. The company’s 50-day simple moving average is $136.25 and its 200 day simple moving average is $139.23.

iShares Biotechnology ETF Increases Dividend

The business also recently disclosed a dividend, which was paid on Friday, March 21st. Stockholders of record on Tuesday, March 18th were paid a $0.1212 dividend. This is a positive change from iShares Biotechnology ETF’s previous dividend of $0.06. The ex-dividend date was Tuesday, March 18th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.